Abstract
The relationship between aberrant expression of cyclin D1 and retinoblastoma (RB) protein and clinicopathological factors was investigated in 80 patients with oesophageal SCC using immunohistochemical analyses. Heterogeneous staining of cancer cell nuclei with antibody to cyclin D1 was found in 31.3% of patients (25 out of 80 patients). Nuclear staining of cancer cells with anti-RB antibody was homogeneous in 10.0% (8 out of 80 patients) and heterogeneous in 58.8% (47 out of 80 patients). Among cases with homogeneous staining for RB protein, 75% (six out of eight patients) exhibited simultaneous positivity for cyclin D1 (P < 0.05). No significant relationship was found between cyclin D1 or RB protein expression and various clinicopathological parameters. The prognosis of patients with cyclin D1-positive tumours was significantly poorer than that of the other patients (P < 0.01). In addition, when patients with cyclin D1-positive and -negative tumours were stratified according to presence or absence of lymph node metastasis and RB status, the cumulative survival rates in the cyclin D1-positive groups were significantly lower for patients without lymph node metastasis (P < 0.01) and for patients whose tumours were positive for RB (P< 0.0001). These findings suggest the possibility that cyclin D1 positivity is a useful prognostic marker related to lymph node metastasis and RB protein expression in human oesophageal SCC, in addition to clinicopathological factors.
Highlights
No significant relationship was found between cyclin Dl protein expression and various clinicopathological parameters, including TNM categories, stage, histological grade, and patient age and sex, or between RB protein expression and clinicopathological parameters
We studied the aberrant expression of cyclin Dl and RB proteins in 80 patients with oesophageal squamous cell carcinoma (SCC) and assessed the relationships between cyclin Dl and RB protein expression and various clinicopathological features of these patients
A total of 31.3% (25 out of 80) of the tumour samples exhibited increased expression of cyclin Dl protein, which was observed predominantly in the nuclei of cancer cells. These findings show a fair correlation with the initial studies performed by Jiang et al (1993) and Tsuruta et al (1993), in which amplification of the cyclin Dl gene was found in 32.0% and 36.4%, respectively, of oesophageal SCC
Summary
Eighty cases of primary human oesophageal SCC consecutively obtained at oesophagectomy in the Department of Surgery II of Kochi Medical School between 1982 and 1996 (78 patients) and the Division of Surgery of Kochi Municipal Central Hospital in 1994 (two patients) were studied. Patients who underwent oesophagectomy in our school had undergone chemotherapy of Immunohistochemistry (IHC) with antibodies to cyclin Dl and RB protein. Cyclin Dl and RB protein expression was assessed by immunohistochemical examination using an anti-human cyclin Dl monoclonal antibody (P2D11Fl1, dilution 1:50, Novocastra, Newcastle, UK) and an British Journal of Cancer (1998) 77(1), 92-97 Cyclin Dl. Positive (1+, 2+) Negative (-). RB positive (1+, 2+) RB negative (-). 3+ was not observed in cyclin Dl expression
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
